What is Celcuity's market cap?

Celcuity (CELC) has a market capitalization of $4.5B and trades on NASDAQ.

Who are Celcuity's competitors?

Celcuity's key competitors include Gilead Sciences, Inc., Verastem, Inc., BridgeBio Pharma Inc., and others. These companies compete in similar markets and product categories.

Who does Celcuity partner with?

Celcuity's notable partners include Pfizer, AstraZeneca, Dana-Farber Cancer Institute, and others.

Where is Celcuity headquartered?

Celcuity is headquartered in United States of America and employs approximately 55 people. It has been publicly traded since 2017.

Celcuity (CELC) Stock Fundamentals & Financials

Celcuity Inc. is a clinical-stage biotechnology company dedicated to developing targeted therapies for multiple solid tumor indications.

Market cap

$4.55B+111%

Net income-$192.9M-51.7%

Free cash flow-$172.9M-68.8%

EPS (diluted)-$3.91-28.2%

Trailing twelve months · change vs. prior year

Earnings

Q1 2026 report

May 14, 2026

EPS-$0.97Beat by $0.10

Read the full report

Next report

Aug 13, 2026 (In 4 days)

Revenue estimate$4.4M

EPS estimate-$1.16

Financials

Q1 2026

Income statement

See full

Operating income-$50.5M-39.8%

Net income-$52.8M-42.8%

EPS (diluted)-$0.97-12.8%

Balance sheet

See full

Cash & equivalents$145.2M+781%

Total debt$137.9M+30.7%

Total equity$53.5M-38.2%

Total assets$410.2M+88.0%

Cash flow

See full

Operating cash flow-$55.1M-53.6%

CapEx$249.0K+315%

Free cash flow-$55.3M-54.0%

Valuation & ratios

Valuation

See full

Market cap$4.55B+111%

Enterprise value$4.54B+142%

Returns & leverage

See full

Return on equity-275.2%-990pp

Debt / equity2.6×+1.4×

Current ratio12.3×+5.7×

Competitors

By market cap

Eli Lilly$1.06T+58.6%

Gilead Sciences$162.47B+18.4%

BridgeBio Pharma$16.2B+89.3%

Celcuity$4.5B+150%

Relay Therapeutics, Inc.$4.3B+611%

Verastem$519.3M+65.2%

Gain Therapeutics$75.9M+42.1%

Instil Bio$49.4M-71.4%

By revenue growth

BridgeBio Pharma+355%

Eli Lilly+49.6%

Relay Therapeutics, Inc.+23.9%

Gilead Sciences+5.5%

By net margin

Eli Lilly33.53%+7.6pp

Gilead Sciences-10.64%-32.5pp

BridgeBio Pharma-125.85%+405pp

Relay Therapeutics, Inc.-2,763.64%+965pp

Profile

Celcuity Inc. is a clinical-stage biotechnology company dedicated to developing targeted therapies for multiple solid tumor indications. The company's core value proposition centers on gedatolisib, a differentiated pan-class I PI3K and mTOR inhibitor designed to comprehensively block the PAM pathway and overcome resistance mechanisms in advanced cancers.

Competitive position

Celcuity is a clinical-stage developer positioning its lead candidate as a potential new standard of care for HR+/HER2- advanced breast cancer following progression on CDK4/6 inhibitors.

GeographiesUnited States, Europe, Asia-Pacific, Latin America

Customer segmentsPatients, Healthcare Providers

Business modelResearch and Development, IP Licensing

SuppliersContract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Pfizer (Licensor), Clinical trial sites

CustomersSpecialty distributors, Third-party logistics providers (3PL), Medical oncologists, Hospitals and cancer centers

CountryUnited States of America

Listed2017

Employees55.0

CEOBrian F. Sullivan

SectorHealthcare

IndustryBiotechnology

Websitecelcuity.com

FilingsSEC EDGAR

FAQ

What is Celcuity's market cap?: Celcuity (CELC) has a market capitalization of $4.5B and trades on NASDAQ.
Who are Celcuity's competitors?: Celcuity's key competitors include Gilead Sciences, Inc., Verastem, Inc., BridgeBio Pharma Inc., and others. These companies compete in similar markets and product categories.
Who does Celcuity partner with?: Celcuity's notable partners include Pfizer, AstraZeneca, Dana-Farber Cancer Institute, and others.
Where is Celcuity headquartered?: Celcuity is headquartered in United States of America and employs approximately 55 people. It has been publicly traded since 2017.